ScripsAmerica's RapiMed(R) Product Generates Tremendous Retail Interest at the 2013 ECRM Cough/Cold, Analgesics & Allergy Conference

NEW CASTLE, Del., Feb. 27, 2013 (GLOBE NEWSWIRE) -- ScripsAmerica, Inc. (OTCBB:SCRC), a leading supplier of prescription, OTC and nutraceutical drugs, today announced that the Company's RapiMed® line of children's pain and fever reliever was extremely well received at the 2013 "Cough/Cold, Analgesics & Allergy EPPS" conference which was held in Destin, Florida from February 17 – 21st.

The annual conference, sponsored by Efficient Collaborative Retail Marketing (ECRM), brings together makers of cough and cold, allergy, analgesics, vaporizers, humidifiers, and digestive branded and private label suppliers to present new programs to North America's top retailers across all channels. ScripsAmerica presented RapiMed® to promote its placement and sale across retail outlets throughout the United States and reports that the Company received verbal order commitments from 62 of 66 retailers that it met with during the conference.

ScripsAmerica's RapiMed® line of orally dissolving pediatric pain and fever relievers seeks to beat McNeil Consumer Healthcare's Tylenol Meltaways' return to the market and win market share over private label manufacturers by promising to melt faster, taste better and be smaller than competing products. RapiMed® also addresses FDA dosing concerns and will target the nation's rapidly growing Hispanic consumer population with labeling in both English and Spanish, which the Company believes will contribute to its competitive advantage.

"ScripsAmerica is pleased to report that our RapiMed® pediatric product was received exceptionally well by retail chains from across the nation at this year's ECRM show. The extremely high number of verbal commitments for product orders we received at the show increases our confidence that RapiMed® will be widely embraced by consumers shopping for a pediatric pain and fever reliever due to its ability to melt faster, taste better and be more accurately dosed than the competing products," commented CEO of ScripsAmerica, Bob Schneiderman.

About ScripsAmerica, Inc.

ScripsAmerica, Inc. delivers pharmaceutical products to a wide range of end users across the health care industry through the largest pharmaceutical distributor in North America, McKesson Corporation. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. Current therapeutic categories serviced by the Company include pain, arthritis, prenatal, urinary, and hormonal replacement drugs. Other customers of ScripsAmerica include Cardinal Health, CutisPharma, Inc., MedVet and the United States Veterans Administration.

For more information, visit

Safe Harbor Statement

This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: 888-959-7095Source:ScripsAmerica, Inc.